Idexx LaboratoriesIDXXEarnings & Financial Report
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
IDXX Q4 FY2025 Key Financial Metrics
Revenue
$1.1B
Gross Profit
$658.1M
Operating Profit
$315.6M
Net Profit
$248.2M
Gross Margin
60.3%
Operating Margin
28.9%
Net Margin
22.8%
YoY Growth
14.3%
EPS
$3.09
Idexx Laboratories Q4 FY2025 Financial Summary
Idexx Laboratories reported revenue of $1.1B (up 14.3% YoY) for Q4 FY2025, with a net profit of $248.2M (up 14.8% YoY) (22.8% margin). Cost of goods sold was $432.5M, operating expenses totaled $342.5M.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $248.2M |
| Gross Margin | 60.3% |
| Operating Margin | 28.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Idexx Laboratories Q4 FY2025 revenue of $1.1B breaks down across 11 segments, led by Vet Lab Consumables at $389.0M (35.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Vet Lab Consumables | $389.0M | 35.7% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32.0% |
| Rapid Assay Products | $76.0M | 7.0% |
| Recurring Revenue | $70.6M | 6.5% |
| CAG Diagnostic Capital Instruments | $58.1M | 5.3% |
| Water Segment | $50.5M | 4.6% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3.4% |
| CAG Diagnostics Service And Accessories | $35.3M | 3.2% |
| Systems And Hardware | $20.1M | 1.8% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0.2% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0.1% |
Idexx Laboratories Revenue by Segment — Quarterly Trend
Idexx Laboratories revenue by segment across the last 4 reported quarters, showing how each business line (such as Vet Lab Consumables and Reference Laboratory Diagnostic And Consulting Services) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Vet Lab Consumables | $389.0M | $387.8M | $375.1M | $344.8M |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | $362.7M | $367.7M | $344.4M |
| Rapid Assay Products | $76.0M | $88.6M | $100.2M | $84.0M |
| Recurring Revenue | $70.6M | $71.0M | $69.0M | $65.8M |
| CAG Diagnostic Capital Instruments | $58.1M | $51.5M | $58.6M | $32.0M |
Idexx Laboratories Annual Revenue by Year
Idexx Laboratories annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.3B).
Idexx Laboratories Quarterly Revenue & Net Profit History
Idexx Laboratories results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1B | +14.3% | $248.2M | 22.8% |
| Q3 FY2025 | $1.1B | +13.3% | $274.6M | 24.8% |
| Q2 FY2025 | $1.1B | +10.6% | $294.0M | 26.5% |
| Q1 FY2025 | $998.4M | +3.6% | $242.7M | 24.3% |
| Q4 FY2024 | $954.3M | +5.8% | $216.1M | 22.7% |
| Q3 FY2024 | $975.5M | +6.6% | $232.8M | 23.9% |
| Q2 FY2024 | $1.0B | +6.4% | $203.3M | 20.3% |
| Q1 FY2024 | $964.1M | +7.1% | $235.6M | 24.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $964.1M | $1.00B | $975.5M | $954.3M | $998.4M | $1.11B | $1.11B | $1.09B |
| YoY Growth | 7.1% | 6.4% | 6.6% | 5.8% | 3.6% | 10.6% | 13.3% | 14.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.35B | $3.41B | $3.35B | $3.29B | $3.21B | $3.33B | $3.39B | $3.35B |
| Liabilities | $1.78B | $1.83B | $1.73B | $1.70B | $1.77B | $1.87B | $1.83B | $1.75B |
| Equity | $1.57B | $1.58B | $1.62B | $1.60B | $1.45B | $1.46B | $1.56B | $1.61B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $198.6M | $248.3M | $220.1M | $262.0M | $238.0M | $185.7M | $402.3M | $355.8M |